CRIO, Inc

Based in the US, CRIO, Inc. provides innovative eSource solutions to enhance clinical trial efficiency through streamlined data capture and real-time monitoring, optimizing data quality and compliance across various clinical research sectors. Founded in 2015 in Boston, US, CRIO, Inc. operates in the clinical research sector, specializing in electronic data collection.

The firm has not reported any significant changes in its business strategy. CEO Raymond N. has extensive experience in the field. The company has raised a total of USD 9.

00 mn through Series B funding led by Abbhi Capital, with the most recent funding round completed on May 21, 2024, bringing its current valuation to USD 39. 67 mn. CRIO offers an innovative eSource solution designed to enhance clinical trial efficiency by streamlining data capture at the point of patient interaction. Their core product, Central eSource™, allows clinical sites to standardize data collection while remaining adaptable to local practices, thus ensuring protocol compliance and improving overall site performance.

By utilizing fully configurable and scalable templates, CRIO’s platform provides real-time data access, facilitating remote monitoring and collaboration among stakeholders. The solution is tailored for a diverse client base, including sponsors, contract research organizations (CROs), academic research institutions, and independent clinical sites across various geographical markets, such as the United States, Canada, Australia, and the European Union. This comprehensive approach addresses the challenges faced by clinical sites, allowing them to focus more on the quality of data rather than administrative burdens. CRIO's revenue generation model primarily revolves around subscription-based transactions with its clients, which include sponsors and CROs.

The company provides its eSource products through tiered pricing plans, allowing clients to choose configurations based on their specific needs and the scale of their clinical trials. This subscription structure facilitates predictable revenue streams as clients commit to ongoing use of CRIO’s technology. The firm’s flagship products, such as Central eSource™, are integral to these transactions, enabling clients to enhance trial efficiency and data integrity. CRIO's revenue is derived from direct business-to-business interactions, as the company collaborates closely with its clients to implement its technology, ensuring compliance and operational excellence in clinical research.

In May 2024, CRIO, Inc. raised an undisclosed amount of venture funding from new investor The Riverside Company. The company will use the funding to expand its product offerings and strengthen its value to clinical research and biopharmaceutical companies. Future initiatives include the planned launch of new products aimed at further improving clinical trial efficiency, as well as expanding into additional markets such as Asia and South America within the next 12 to 18 months.